BIONEWS
In Q Tel, the BioNTech co founder's family office, and the Slovak government are betting on a startup that wants to replace 40 year old mRNA chemistry with engineered cells.
For more than 40 years, mRNA drugs have been brewed the same way: in a chemical vat. Sensible Biotechnologies, a Slovakia-based startup, wants to brew them in a living cell instead.
The company raised $47 million this week to scale a manufacturing platform that uses engineered eukaryotic cells — the kind of cells that already run a human body — to produce mRNA. Today's mRNA medicines, including the COVID vaccines, are built by in-vitro transcription, a synthetic-chemistry process that has dominated the field for decades. Sensible says its cell-based approach produces "naturally modified" mRNA with fewer unwanted immune reactions and less contamination from double-stranded RNA, the unwanted side products that can trigger inflammation.
The funding structure is the story. About $27 million is Series A equity from OTB Ventures and In-Q-Tel, the US intelligence community's venture arm. The remaining up to $20 million is non-dilutive capital from the Government of Slovakia and the European Union, structured to underwrite platform-manufacturing risk that venture capital typically avoids. Public money sitting alongside private capital is what makes this round different, not the size. It also signals that Slovakia is treating Sensible as a national biotech bet.
The platform itself is called VECTOR, or Versatile Engine for Cell-based Therapeutic Optimization of RNA. It pairs computational and AI-enabled sequence design with high-throughput screening, then runs the winning sequences through engineered cells that manufacture the molecule. A companion technology called PromPT captures and protects the mRNA inside the cell before purification, addressing one of the yield-killing steps in conventional processes.
The new capital is earmarked to advance and scale the platform, not to fund named clinical trials, and the company has not disclosed preclinical or clinical efficacy data. Co-founder and CEO Miroslav Gasparek framed the round as a vote of confidence in the manufacturing thesis: mRNA's reach beyond COVID has been limited by what can be made cheaply and at scale, he said, and Sensible believes the production method, not the sequence, is the bottleneck.
Returning investors include Recode Ventures, Isomer Capital, Y Combinator, Backed VC, Kaya VC, Civilization Ventures, BlueYard Capital, the family office of Christoph Huber, and Tim Garnett.
The credibility signal is real, and so is the evidence gap. Sensible's claims about reduced immunogenicity and avoidance of double-stranded RNA contamination have not been validated in a peer-reviewed paper the company has disclosed. The VECTOR platform has not yet produced a clinical candidate. The partnership with Sartorius Stedim Biotech on bioprocessing, flagged in the trade press as a manufacturing-credibility anchor, has not been detailed in a public technical document. Until those appear, "cell-based mRNA" remains a company-stated category rather than an established one.
What to watch next: a peer-reviewed paper validating the VECTOR mechanism, the first named preclinical candidate, and a public technical disclosure from the Sartorius Stedim bioprocessing partnership. The manufacturing bet becomes credible when at least one of those is on paper.